Alexis Peyroles
Vermögen: 640 301 $ am 31.10.2026
Vermögen: 640 301 $ am 31.10.2026
Mr. Alexis Peyroles is an Independent Director at OSE Immunotherapeutics SA, a Chief Executive Officer & Director at Betaglue Technologies SpA, a Chairman & Chief Financial Officer at Inside Therapeutics SAS, a Chairman at Aperana Consulting SAS and a Chief Executive Officer at OSE Immunotherapeutics, Inc. He is on the Board of Directors at OSE Immunotherapeutics SA and Betaglue Technologies SpA. Mr. Peyroles was previously employed as a CFO & Head-Business Development by Orphan Synergy Europe-Pharma SA, a Chief Executive Officer by Guerbet Imagem do Brasil Ltda., a Manager-Financial Control by Guerbet SA, a Head-Eastern Europe Business Development by Sanofi-Aventis France SA, and a Head-Financial Control-Baltic States by Sanofi-Aventis Japan.
He received his undergraduate degree from École des Hautes Études Commerciales du Nord and an MBA from Imperial College Business School.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 30.09.2025 | 293.848 ( 1,25 % ) | 640 301 $ | 31.10.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Direktor/Vorstandsmitglied | 30.09.2025 |
Ose Immunotherapeutics, Inc. | Vorstandsvorsitzender | - |
Betaglue Technologies SpA
Betaglue Technologies SpA Miscellaneous Commercial ServicesCommercial Services Operates as a biotech company that manufacture oncology therapeutic products | Vorstandsvorsitzender | 22.09.2025 |
Aperana Consulting SAS | Vorsitzender | - |
| Unternehmen | Position | Ende |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Vorstandsvorsitzender | 16.01.2022 |
Sanofi-Aventis Japan | Comptroller/Controller/Auditor | - |
| GUERBET | Comptroller/Controller/Auditor | - |
Sanofi-Aventis France SA
Sanofi-Aventis France SA Medical DistributorsDistribution Services Wholesales pharmaceutical products | Corporate Officer/Principal | - |
Orphan Synergy Europe-Pharma SA
Orphan Synergy Europe-Pharma SA Pharmaceuticals: MajorHealth Technology Develops immunotherapy products for late-stage cancers | Finanzdirektor/CFO | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 11 |
|---|---|
Guerbet SA
Guerbet SA Medical SpecialtiesHealth Technology Engages in research, development and production of X-Rays and its by products | Health Technology |
Sanofi-Aventis Japan | |
École des Hautes Études Commerciales du Nord
École des Hautes Études Commerciales du Nord Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sanofi-Aventis France SA
Sanofi-Aventis France SA Medical DistributorsDistribution Services Wholesales pharmaceutical products | Distribution Services |
Orphan Synergy Europe-Pharma SA
Orphan Synergy Europe-Pharma SA Pharmaceuticals: MajorHealth Technology Develops immunotherapy products for late-stage cancers | Health Technology |
Imperial College Business School
Imperial College Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aperana Consulting SAS | |
OSE Immunotherapeutics SA
OSE Immunotherapeutics SA Pharmaceuticals: MajorHealth Technology Develops immunotherapy products for late-stage cancers | Health Technology |
Betaglue Technologies SpA
Betaglue Technologies SpA Miscellaneous Commercial ServicesCommercial Services Operates as a biotech company that manufacture oncology therapeutic products | Commercial Services |
Ose Immunotherapeutics, Inc. | |
Guerbet Imagem do Brasil Ltda. |
Bitte wählen Sie Ihre Edition
Alle länderspezifischen Finanzinformationen